<DOC>
	<DOCNO>NCT00160069</DOCNO>
	<brief_summary>Phase 2 study investigate efficacy tolerability epothilone ZK 219477 patient stage IIIb stage IV non-small-cell lung cancer .</brief_summary>
	<brief_title>Safety Efficacy Study New Chemotherapy Agent Treat Non-small-cell Lung Cancer</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<criteria>Nonsmallcell lung cancer Only one previous chemotherapy platinumcontaining drug Use highly effective birth control method female childbearing potential No 1 previous chemotherapy advance disease Previous participation another trial within last 4 week Breast feed Active infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Stage IIIB stage IV non-small-cell lung cancer .</keyword>
</DOC>